Related references
Note: Only part of the references are listed.Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response
Ruediger Braun et al.
CELLS (2023)
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Hannah L. Williams et al.
CANCER RESEARCH (2023)
E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10
Ting Zhang et al.
CANCER SCIENCE (2022)
c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
Jingjing Yao et al.
FRONTIERS IN PHARMACOLOGY (2022)
The Quasimesenchymal Pancreatic Ductal Epithelial Cell Line PANC-1-A Useful Model to Study Clonal Heterogeneity and EMT Subtype Shifting
Hendrik Ungefroren et al.
CANCERS (2022)
Testis-expressed gene 11 inhibits cisplatin-induced DNA damage and contributes to chemoresistance in testicular germ cell tumor
Sachi Kitayama et al.
SCIENTIFIC REPORTS (2022)
Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses
Humberto Contreras-Trujillo et al.
NATURE COMMUNICATIONS (2021)
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Aubrey L. Miller et al.
CANCERS (2021)
yBlockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness
Chao Jing et al.
THERANOSTICS (2021)
DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput
Vadim Demichev et al.
NATURE METHODS (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Michelle Chan-Seng-Yue et al.
NATURE GENETICS (2020)
Single-Cell-Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response
Rudiger Braun et al.
CLINICAL CANCER RESEARCH (2020)
mitch: multi-contrast pathway enrichment for multi-omics and single-cell profiling data
Antony Kaspi et al.
BMC GENOMICS (2020)
Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype
Natalia Juiz et al.
FASEB JOURNAL (2020)
stratifyR: An R Package for optimal stratification and sample allocation for univariate populations
K. G. Reddy et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF STATISTICS (2020)
Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer
Kim C. Honselmann et al.
MOLECULAR CANCER RESEARCH (2020)
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Wei Lin et al.
GENOME MEDICINE (2020)
Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors
Sahil Seth et al.
CELL REPORTS (2019)
Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
Benjamin Bian et al.
FRONTIERS IN ONCOLOGY (2019)
UniProt: a worldwide hub of protein knowledge
Alex Bateman et al.
NUCLEIC ACIDS RESEARCH (2019)
The PRIDE database and related tools and resources in 2019: improving support for quantification data
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2019)
DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3 beta/beta-catenin signaling pathway
Hua Ge et al.
ONCOTARGETS AND THERAPY (2018)
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
Fang Xie et al.
SCIENTIFIC REPORTS (2018)
E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
Wenjun Lan et al.
SCIENTIFIC REPORTS (2018)
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance
Xin Lai et al.
THERANOSTICS (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition
Eric W. Deutsch et al.
NUCLEIC ACIDS RESEARCH (2017)
Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma
Xiaoping Liu et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2017)
Differential analysis of RNA-seq incorporating quantification uncertainty
Harold Pimentel et al.
NATURE METHODS (2017)
Combating subclonal evolution of resistant cancer phenotypes
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2017)
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
Amy S. Farrell et al.
NATURE COMMUNICATIONS (2017)
MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy
Yichen Meng et al.
SCIENTIFIC REPORTS (2017)
Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
Benjamin Bian et al.
EMBO MOLECULAR MEDICINE (2017)
Gemcitabine treatment promotes pancreatic cancer sternness through the Nox/ROS/NF-κB/STAT3 signaling cascade
Zhengle Zhang et al.
CANCER LETTERS (2016)
On the Dependency of Cellular Protein Levels on mRNA Abundance
Yansheng Liu et al.
CELL (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC
Yan-Ping Liu et al.
ONCOTARGET (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Hyo-eun C. Bhang et al.
NATURE MEDICINE (2015)
Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
Sophia Pinz et al.
NUCLEIC ACIDS RESEARCH (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
The evolution of the unstable cancer genome
Rebecca A. Burrell et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ
Juergen Cox et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
DcR3 regulates the growth and metastatic potential of SW480 colon cancer cells
Wei Yu et al.
ONCOLOGY REPORTS (2013)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
Bo Huang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
The Interaction of NSBP1/HMGN5 with Nucleosomes in Euchromatin Counteracts Linker Histone-Mediated Chromatin Compaction and Modulates Transcription
Mark Rochman et al.
MOLECULAR CELL (2009)
Building Predictive Models in R Using the caret Package
Max Kuhn
JOURNAL OF STATISTICAL SOFTWARE (2008)
In vivo identification of novel STAT5 target genes
Beth Basham et al.
NUCLEIC ACIDS RESEARCH (2008)
Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
A Arlt et al.
ONCOGENE (2003)
The function of multiple IκB:NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis
QG Dong et al.
ONCOGENE (2002)
Share Paper
